The oncology clinical trial market share is expected to increase by USD 4.22 billion from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 6.70%.
This oncology clinical trial market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers oncology clinical trial market segmentation by design (interventional, observational, and expanded access) and geography (North America, Europe, Asia, and ROW). The oncology clinical trial market report also offers information on several market vendors, including F. Hoffmann-La Roche Ltd., Icon Plc, IQVIA Holdings Inc., Medpace Holdings Inc., Merck and Co. Inc., Novartis AG, Novotech (Australia) Pty Ltd., Parexel International Corp., Pivotal S.L.U, and Syneos Health Inc. among others.
What will the Oncology Clinical Trial Market Size be During the Forecast Period?
Download the Free Report Sample to Unlock the Oncology Clinical Trial Market Size for the Forecast Period and Other Important Statistics
Oncology Clinical Trial Market: Key Drivers and Challenges
The increasing number of cancer cases across the globe is notably driving the oncology clinical trial market growth, although factors such as inefficient clinical trial design for oncology may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the oncology clinical trial industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Oncology Clinical Trial Market Driver
The number of cancer cases is rising on a global level due to increased pollution and frequent changes in lifestyle. Exposure to carcinogens has increased as the global air quality index has degraded. Pharmaceutical companies and various government organizations are developing new and improved treatments for multiple types of cancers and scheduling oncology clinical trials to get the treatments approved by relevant agencies, which, in turn, will drive the demand for oncology clinical trials during the forecast period.
Key Oncology Clinical Trial Market Challenge
Clinical trials are subject to errors, and oncology clinical trials need to be thorough. The data collection method may be inefficient, and the researchers may not get full disclosure from patients participating in trials. This leads to misinformation resulting in wrongful conclusions, which hamper the oncology study for which the clinical trial was conducted. Other factors such as inappropriate selection of clinical trial candidates and error in clinical trial design may damage the study. Hence, the global market for oncology clinical trials can be restricted by inefficient clinical trial designs.
This oncology clinical trial market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Who are the Major Oncology Clinical Trial Market Vendors?
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
- F. Hoffmann-La Roche Ltd.
- Icon Plc
- IQVIA Holdings Inc.
- Medpace Holdings Inc.
- Merck and Co. Inc.
- Novartis AG
- Novotech (Australia) Pty Ltd.
- Parexel International Corp.
- Pivotal S.L.U
- Syneos Health Inc.
This statistical study of the oncology clinical trial market encompasses successful business strategies deployed by the key vendors. The oncology clinical trial market is fragmented and the vendors are deploying growth strategies such as focusing on product innovation and spending in research and development activities to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The oncology clinical trial market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Which are the Key Regions for Oncology Clinical Trial Market?
For more insights on the market share of various regions Request for a FREE sample now!
40% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for oncology clinical trials in North America. However, the market growth rate in this region will be slower than the growth of the market in Asia and Europe.
This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
What are the Revenue-generating Design Segments in the Oncology Clinical Trial Market?
To gain further insights on the market contribution of various segments Request for a FREE sample
The oncology clinical trial market share growth by the interventional segment will be significant during the forecast period. This report provides an accurate prediction of the contribution of all the segments to the growth of the oncology clinical trial market size and actionable market insights on post COVID-19 impact on each segment.
|
Oncology Clinical Trial Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2020 |
|
Forecast period |
2021-2025 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 6.70% |
|
Market growth 2021-2025 |
$ 4.22 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
5.11 |
|
Regional analysis |
North America, Europe, Asia, and ROW |
|
Performing market contribution |
North America at 40% |
|
Key consumer countries |
US, Germany, Canada, UK, and China |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
F. Hoffmann-La Roche Ltd., Icon Plc, IQVIA Holdings Inc., Medpace Holdings Inc., Merck and Co. Inc., Novartis AG, Novotech (Australia) Pty Ltd., Parexel International Corp., Pivotal S.L.U, and Syneos Health Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
What are the Key Data Covered in this Oncology Clinical Trial Market Report?
- CAGR of the market during the forecast period 2021-2025
- Detailed information on factors that will drive oncology clinical trial market growth during the next five years
- Precise estimation of the oncology clinical trial market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the oncology clinical trial industry across North America, Europe, Asia, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of oncology clinical trial market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch